Albireo Pharma, Inc.
Albireo Pharma, Inc. (ALBO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
albo · pe ratio · data through Dec 31, 2021
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Albireo Pharma, Inc. (ALBO) measures how much investors pay for each dollar of the company's trailing earnings. ALBO's current PE ratio of N/A is calculated by dividing its stock price of $44.15 by its TTM earnings per share of -$7.87.
Source: FMP · /ratios-ttm · /analyst-estimates · 2021-12-31
PE Ratio History
2004 – 2021 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Albireo Pharma, Inc.You ALBO | $916M | N/A | — | -$7.87 |
 Crescent Biopharma, Inc. CBIO | $476M | N/A | — | -$14.78 |
 Avid Bioservices, Inc. CDMO | $799M | N/A | — | -$2.23 |
 Chimerix, Inc. CMRX | $801M | N/A | — | -$0.99 |
 Gracell Biotechnologies Inc. GRCL | $198M | N/A | — | -$44.87 |
 Harpoon Therapeutics, Inc. HARP | $865M | N/A | — | -$20.24 |
 Intercept Pharmaceuticals, Inc. ICPT | $795M | 3.63x | — | $3.41 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2021-12-31Latest FY2021 | — | $-7.87 | — | |
2020-12-31 FY2020 | — | $-7.45 | — | |
2019-12-31 FY2019 | — | $-5.76 | — | |
2018-12-31 FY2018 | — | $-3.94 | — | |
2017-12-31 FY2017 | — | $-3.12 | — | |
2016-12-31 FY2016 | — | $-13.19 | — | |
2015-09-30 FY2015 | — | $-13.71 | — | |
2014-09-30 FY2014 | — | $-19.81 | — | |
2013-09-30 FY2013 | — | $-37.06 | — | |
2012-09-30 FY2012 | — | $-57.19 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Albireo Pharma, Inc. (ALBO) measures how much investors pay for each dollar of the company's trailing earnings. ALBO's current PE ratio of N/A is calculated by dividing its stock price of $44.15 by its TTM earnings per share of -$7.87.
Frequently asked questions
ALBO pe ratio · 6 questionsALBO's current PE ratio is N/A as of 2026-06-09, based on a stock price of $44.15 and TTM EPS of -$7.87. Data sourced from Financial Modeling Prep via ALBO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Albireo Pharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09